Rare blood sits at the center of this dementia and brain health question.
Soliris, the brand name for eculizumab, costs approximately $700,000 per patient per year, making it one of the most expensive drugs ever brought to market. Forbes historically called it “the world’s most expensive drug.” And yet, for the small number of people living with paroxysmal nocturnal hemoglobinuria, a rare and potentially fatal blood disorder, this drug is not a luxury. It is the difference between a drastically shortened life and something close to a normal one. Before Soliris received FDA approval in 2007, the median survival for PNH patients was just 10 to 15 years after diagnosis.
Today, patients on complement inhibitor therapy can achieve near-normal life expectancy. The price tag raises uncomfortable but important questions about how we value human life, how drug pricing works for ultra-rare diseases, and whether newer alternatives might finally bring costs down. This article examines why Soliris costs what it does, how paroxysmal nocturnal hemoglobinuria destroys the body without treatment, what newer competitors like Ultomiris and Fabhalta mean for patients and payers, and why the broader conversation about rare disease drug pricing matters far beyond this single medication. We will also look at hemophilia B, another blood disorder with strikingly similar annual treatment costs, and at gene therapies that may eventually reshape the economics of rare disease care entirely.
Table of Contents
- Why Does This Rare Blood Disease Drug Cost $700,000 Per Year?
- What Paroxysmal Nocturnal Hemoglobinuria Does to the Body Without Treatment
- How Soliris Changed the Prognosis for PNH Patients
- Newer Alternatives Are Cheaper, and Some May Be Better
- The Broader Problem of Rare Disease Drug Pricing
- What This Means for Brain Health and Neurological Conditions
- Where Rare Disease Treatment Goes From Here
- Conclusion
- Frequently Asked Questions
Why Does This Rare Blood Disease Drug Cost $700,000 Per Year?
The short answer is math. Paroxysmal nocturnal hemoglobinuria affects roughly 6 in every 1 million people per year. That means the entire addressable patient population for a PNH drug is vanishingly small. Pharmaceutical companies spend hundreds of millions, sometimes billions, developing a new therapy, running clinical trials, navigating regulatory approval, and building manufacturing capacity. When those costs must be recovered from a few thousand patients worldwide rather than millions, the per-patient price rises to levels that seem almost absurd in isolation. Soliris, manufactured by Alexion Pharmaceuticals (acquired by AstraZeneca in 2021), carries a US acquisition cost of roughly $6,830 per 300-mg vial, with infusions required every two weeks for maintenance dosing. The Orphan Drug Act, passed in 1983, was specifically designed to make drugs like Soliris possible.
It offers manufacturers seven years of market exclusivity, tax credits for clinical trial costs, and other incentives to develop treatments for diseases affecting fewer than 200,000 Americans. Without these protections, companies would have little financial reason to invest in PNH research at all. The tradeoff is real: the law encourages development for desperate patient populations, but it also creates conditions where a single company can dominate a tiny market with limited pricing pressure. Alexion’s revenue from Soliris exceeded $4 billion annually at its peak, drawn from a global patient base of only a few thousand people. It is worth noting that the $700,000 figure reflects approximate Canadian pricing. In the United States, the actual annual cost varies depending on insurance negotiations, patient weight, and dosing schedules, but specialty pharmacy reports from organizations like Prime Therapeutics have placed C5 inhibitor therapy costs between $300,000 and $600,000 or more per year. By any measure, it sits among the highest-cost specialty drug categories in existence.
What Paroxysmal Nocturnal Hemoglobinuria Does to the Body Without Treatment
PNH is caused by a somatic mutation in the PIGA gene, which leaves red blood cells without a critical surface protein that protects them from the body’s own complement system. In healthy people, the complement system is part of the immune response, designed to attack foreign invaders. In PNH patients, it turns on the body’s own red blood cells and destroys them, a process called hemolysis. The result is chronic, sometimes severe anemia, dark-colored urine (particularly noticeable in the morning, which gives the disease its name), crushing fatigue, kidney damage, and abdominal pain. The most dangerous complication is thrombosis. Blood clots are the leading cause of death in untreated PNH patients, and they can form in unusual locations, including the veins of the liver, brain, and abdomen.
Without treatment, the disease follows a grim trajectory: repeated transfusions, organ damage, declining quality of life, and a median survival of 10 to 15 years after diagnosis. For a disease that can strike adults in their twenties and thirties, that timeline is devastating. However, PNH severity varies significantly from patient to patient. Some individuals have relatively mild hemolysis and may go years before the disease is recognized. Others experience life-threatening crises. This variability makes diagnosis difficult and means some patients spend months or years seeing specialists before receiving a correct diagnosis. The rarity of the condition, just 6 per million, means many physicians will never encounter a single case in their careers, which compounds the diagnostic delay.
How Soliris Changed the Prognosis for PNH Patients
When eculizumab entered clinical trials in the mid-2000s, it was the first drug to directly target complement-mediated hemolysis in PNH. The results were striking. In clinical trials, 26 weeks of treatment achieved stabilization of hemoglobin levels in significantly more patients compared to placebo. Patients required fewer blood transfusions. The risk of life-threatening blood clots dropped substantially. For a population that had been managed primarily with supportive care, transfusions, and anticoagulants, Soliris represented a genuine transformation. Consider what “worth it” means from a patient perspective.
Before 2007, a 30-year-old diagnosed with PNH faced a statistical life expectancy of roughly 40 to 45 years of age. On Soliris, that same patient could reasonably expect to live into their seventies or beyond. The drug did not cure PNH. Patients must continue biweekly infusions indefinitely. But it converted a progressive, fatal disease into a manageable chronic condition, similar in concept to insulin for type 1 diabetes or antiretroviral therapy for HIV. Soliris also received FDA approval for three additional conditions: atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder. The last of these is particularly relevant to readers interested in neurological health, as neuromyelitis optica spectrum disorder is an autoimmune condition that attacks the optic nerves and spinal cord, and complement inhibition has shown meaningful benefit for these patients as well.
Newer Alternatives Are Cheaper, and Some May Be Better
The market for PNH treatment is no longer a monopoly. Several competitors have entered or are entering the space, and they offer meaningful advantages over Soliris in both cost and convenience. Ultomiris (ravulizumab), also made by Alexion, is a next-generation C5 complement inhibitor with a longer half-life. It requires infusions every eight weeks instead of every two, which dramatically reduces the burden on patients and infusion centers. Its annual cost runs between $400,000 and $500,000 per year, roughly a 33 percent reduction compared to Soliris for maintenance therapy. Empaveli (pegcetacoplan), developed by Apellis Pharmaceuticals, takes a different approach by targeting complement component C3 rather than C5. In cost-effectiveness analyses, Empaveli has been described as dominant over eculizumab, meaning it delivers better clinical outcomes at lower total cost, with estimated savings of approximately $1.17 million per patient over the treatment horizon.
Perhaps most notable is Fabhalta (iptacopan), an oral Factor B inhibitor from Novartis approved in 2023. For the first time, PNH patients have a pill-based option rather than intravenous infusions. Recent 2025 cost-per-responder analyses suggest Fabhalta offers greater clinical utility than C5 inhibitors. The tradeoff is that newer does not always mean universally better for every patient. Some individuals respond well to C5 inhibitors but may not be candidates for C3 or Factor B inhibition due to their specific disease profile, prior treatment history, or risk factors for certain infections. Complement inhibitors of all types increase susceptibility to infections with encapsulated bacteria, particularly Neisseria meningitidis, requiring vaccination before starting treatment. Patients switching between drug classes need careful medical supervision during the transition period.
The Broader Problem of Rare Disease Drug Pricing
Soliris is not an isolated case. The economics that produce a $700,000-per-year drug for PNH are the same economics driving prices across the rare disease landscape. Orphan drugs are projected to account for roughly 20 percent of all prescription drug sales by 2026, despite treating a fraction of a percent of the population. Hemophilia B, another rare blood disorder, offers a striking parallel: annual treatment costs for factor IX replacement therapy average $700,000 to $800,000 per year in the United States, with lifetime treatment costs that can exceed $20 million per patient. The gene therapy Hemgenix (etranacogene dezaparvovec), approved for hemophilia B, carries a price of $3.5 million for a single treatment, making it the most expensive single drug in the world.
Yet economic modeling suggests it could save $5 to $5.8 million per patient over a lifetime compared to ongoing factor replacement therapy. That math illustrates both the promise and the paradox of rare disease treatment: a one-time $3.5 million expenditure is actually the cheaper option when the alternative is $700,000 every year for decades. The limitation of this argument is that it depends entirely on the gene therapy working as projected over the long term. If durability falls short, if patients need retreatment, or if complications emerge years later, the cost-effectiveness calculations change dramatically. Payers, insurers, and health systems are understandably cautious about committing millions upfront based on clinical trial data that may only span a few years. This uncertainty is one of the central tensions in rare disease medicine, and it has no easy resolution.
What This Means for Brain Health and Neurological Conditions
The complement system that Soliris targets is not only active in blood disorders. Complement-mediated inflammation plays a role in several neurological conditions, including neuromyelitis optica spectrum disorder (for which Soliris is already approved), Alzheimer’s disease research, and certain forms of neuroinflammation being studied in the context of cognitive decline. The success of complement inhibition in PNH has opened research pathways that may eventually benefit patients with brain diseases, though these applications remain largely investigational.
For families navigating dementia care, the Soliris story offers a broader lesson about advocacy. Many PNH patients fought for years to get their insurers and national health systems to cover the drug. In Canada, patients like those profiled by CBC News faced situations where a life-saving medication existed but was not covered by their provincial drug plan. The advocacy skills those patients and families developed, learning to navigate appeals processes, working with patient organizations, engaging with policymakers, are the same skills that families dealing with Alzheimer’s, frontotemporal dementia, and other neurodegenerative conditions need when fighting for access to emerging treatments.
Where Rare Disease Treatment Goes From Here
The trajectory for PNH treatment suggests a pattern that may repeat across rare diseases: a breakthrough drug arrives at an extraordinary price, competition eventually emerges, and costs begin to decline while treatment options improve. The shift from biweekly infusions with Soliris to every-eight-week infusions with Ultomiris to oral daily pills with Fabhalta represents genuine progress in patient quality of life. If gene therapies for blood disorders continue to advance, we may eventually see one-time curative treatments for PNH as well, following the Hemgenix model from hemophilia B.
The challenge ahead is ensuring that these treatments reach the patients who need them, not just in wealthy nations with robust insurance systems, but globally. An ultra-rare disease affecting 6 in every million people means there are PNH patients in every country on earth, and most of them have no access to complement inhibitors at any price. The conversation about whether $700,000 per year is “worth it” looks very different depending on where you are standing when you ask the question.
Conclusion
Soliris transformed paroxysmal nocturnal hemoglobinuria from a disease with a median survival of 10 to 15 years into a manageable condition compatible with a near-normal lifespan. Its approximately $700,000 annual price tag is a direct consequence of developing a drug for a population of roughly 6 per million people, and the Orphan Drug Act incentives that made its development financially viable. Newer competitors including Ultomiris, Empaveli, and the oral option Fabhalta are bringing costs down and improving convenience, but the fundamental tension between rare disease economics and affordability remains unresolved.
For patients and families dealing with any serious medical condition, the story of Soliris is ultimately about the value we place on extending and improving human life. The same debates playing out around PNH drug pricing are now emerging around Alzheimer’s treatments, gene therapies, and other high-cost interventions for devastating diseases. Understanding how these pricing dynamics work, and how patients have successfully advocated for coverage, is practical knowledge that extends well beyond any single diagnosis.
Frequently Asked Questions
What is paroxysmal nocturnal hemoglobinuria (PNH)?
PNH is an ultra-rare blood disorder affecting approximately 6 in every 1 million people per year. It is caused by a mutation in the PIGA gene that leaves red blood cells vulnerable to destruction by the body’s complement immune system, leading to anemia, blood clots, organ damage, and shortened life expectancy without treatment.
Why does Soliris cost $700,000 per year?
The high cost is primarily driven by the extremely small patient population. Pharmaceutical development costs that would normally be spread across millions of patients must be recouped from only a few thousand worldwide. The Orphan Drug Act also grants extended market exclusivity, which limits pricing competition for the initial years after approval.
Are there cheaper alternatives to Soliris for PNH?
Yes. Ultomiris (ravulizumab) costs $400,000 to $500,000 per year and requires infusions only every eight weeks. Empaveli (pegcetacoplan) has shown cost advantages over Soliris in analyses. Fabhalta (iptacopan), approved in 2023, is the first oral treatment option for PNH and has demonstrated strong clinical utility in recent analyses.
Does insurance cover Soliris and similar PNH drugs?
Most major insurance plans and government programs in the US do cover complement inhibitor therapy for PNH, though patients may face prior authorization requirements, step therapy protocols, and copay obligations. Coverage varies significantly by country, and some patients have had to appeal denials or engage in advocacy to secure coverage.
What is the most expensive drug in the world?
As of 2025, Hemgenix (etranacogene dezaparvovec), a one-time gene therapy for hemophilia B, holds the record at $3.5 million per treatment. However, it is projected to save $5 to $5.8 million per patient over a lifetime compared to ongoing factor IX replacement therapy, which costs $700,000 to $800,000 annually.
Is there a connection between complement inhibitors and brain health?
The complement system is active in neurological conditions as well as blood disorders. Soliris is already FDA-approved for neuromyelitis optica spectrum disorder, and complement-mediated inflammation is an active area of research in Alzheimer’s disease and other neurodegenerative conditions, though most brain health applications remain investigational.
You Might Also Like
- Hidradenitis Suppurativa: The Biologic Finally Clearing This Painful Skin Disease
- SPRAVATO Nasal Spray for Depression: Who It’s For and What It Costs
- New Drug Approved for Alcohol Use Disorder — First in 20 Years
For more, see Alzheimer’s Association — clinical trials.
